De Novo device
picoAMH ELISA
Ansh Labs, LLC · Menopause Test System (QDH, Class II) · First FDA decision Oct 24, 2018, newest Oct 24, 2018Menopause and vaginal health
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
0
Naming "picoAMH ELISA"
MAUDE reports
0
Brand "picoAMH ELISA", since 2015
PubMed studies
8
Mentioning "picoAMH ELISA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing picoAMH ELISA
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- picoAMH ELISANew device typeDe Novo
DEN180004 · Decided Oct 24, 2018 · 275 days after receipt
Device type: Menopause Test System (QDH) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "picoAMH ELISA", any status and sponsor, newest update first.
No registered device study names "picoAMH ELISA".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "picoAMH ELISA", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QDH
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "picoAMH ELISA"[tiab]. The summary above synthesizes these.
- Heavy Metals and Trajectories of Anti-Müllerian Hormone During the Menopausal Transition.
Ding N, Wang X, Harlow SD, et al. · J Clin Endocrinol Metab · 2024Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.
- Can highly sensitive antimüllerian hormone testing predict failed response to ovarian stimulation?
Burks HR, Ross L, Opper N, et al. · Fertil Steril · 2015
- A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay.
Welsh P, Smith K, Nelson SM · Hum Reprod · 2014Comparative Study, Evaluation Study
- Validation of the picoAMH assay on the Dynex DS2 platform.
Garnett ER, Jariwala P, Rector K, et al. · Pract Lab Med · 2019
- Association of ovarian response with picoAMH in women undergoing controlled ovarian hyperstimulation.
Bruno-Gaston J, Jung J, Kumar T, et al. · Clin Biochem · 2021
- Outdoor air pollution and anti-Müllerian hormone concentrations in the Sister Study.
Gregoire AM, Upson K, Niehoff NM, et al. · Environ Epidemiol · 2021
- Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.
Jung S, Allen N, Arslan AA, et al. · Fertil Steril · 2017Multicenter Study
- Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy.
Decanter C, Cloquet M, Dassonneville A, et al. · Reprod Biomed Online · 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.